BriaCell Therapeutics Corp.
@BriaCell
Followers
5,933
Following
534
Media
444
Statuses
936
An immuno-oncology company developing targeted and effective immunotherapies for advanced breast cancer and other cancers. (Nasdaq: $BCTX, $BCTXW) (TSX: BCT)
Philadelphia, PA
Joined November 2014
Don't wanna be here?
Send us removal request.
Explore trending content on Musk Viewer
ميلان
• 1424312 Tweets
الاهلي
• 856927 Tweets
نابولي
• 663958 Tweets
Rogan
• 300218 Tweets
Amorim
• 235090 Tweets
Southport
• 150491 Tweets
#النصر_التعاون
• 101611 Tweets
Scary Movie
• 90717 Tweets
Valencia
• 83611 Tweets
Wikipedia
• 52400 Tweets
رونالدو
• 43283 Tweets
SÃO PAULO TOMORROW
• 41252 Tweets
كاس الملك
• 32466 Tweets
Teri Garr
• 32166 Tweets
Colts
• 28968 Tweets
Richardson
• 26100 Tweets
Brenda
• 21188 Tweets
القصيم
• 19055 Tweets
Leao
• 17875 Tweets
Cindy
• 17395 Tweets
علي سالم
• 16499 Tweets
كريستيانو
• 16116 Tweets
Concord
• 15816 Tweets
Young Frankenstein
• 14646 Tweets
Tootsie
• 14323 Tweets
Flacco
• 13781 Tweets
Diontae Johnson
• 13587 Tweets
Al Nassr
• 13227 Tweets
Firewalk
• 10554 Tweets
BriaCell's registration-enabling pivotal Phase 3 study of its lead clinical candidate, Bria-IMT™, in combination with an immune check point inhibitor, is approved by the IRB & will soon enroll patients with advanced metastatic
#breastcancer
. $BCTX $BCTXW
16
61
403
How Bria-IMT™ and Bria-OTS™ Destroy Cancer Cells (Video)
1
24
65
BriaCell has entered into a research collaboration and license agreement with
@ImmunoPrecise
's subsidiary
@BioStrandBV
to discover and develop anti-cancer antibodies. Find details: $BCTX $BCTXW $IPA
9
14
59
BriaCell's lead drug candidate, Bria-IMT™ (awarded Fast Track designation by the FDA), is a targeted
#immunotherapy
in phase I/IIa clinical testing for the treatment of advanced
#breastcancer
. Learn more: $BCTX $BCTXW
3
11
46
Dr. William V. Williams, BriaCell’s President & CEO, comments on positive
#breastcancer
efficacy data with Bria-IMT™
#immunotherapy
presented at the Company's poster session at the
@sitcancer
37th Annual Meeting. Read more: $BCTX $BCTXW
7
13
49
BriaCell announced it has received agreement & positive feedback from its End of Phase II meeting with the FDA for BriaCell’s lead clinical candidate, Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic
#breastcancer
. $BCTX $BCTXW
3
12
46
BriaCell Receives FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy
0
15
38
BriaCell; FDA Fast Track Approval for Targeted Breast Cancer Immunotherapy Received
#breastcancer
#breastcancertreatments
#cancertreatments
#cancer
#research
2
10
35
BriaCell today issues a letter to shareholders from Dr. William V. Williams, BriaCell's President and CEO. Read more: $BCTX $BCTXW
3
7
32
Exciting news in breast cancer research. BriaCell is exploiting this biomarker in novel ways to personalize immunotherapy.
2
9
29
BriaCell announced that it has received approval from
@US_FDA
on its pivotal registrational study design for Bria-IMT™ in combination with a checkpoint inhibitor in advanced metastatic
#breastcancer
. For additional details: $BCTX $BCTXW
2
9
27
BriaCell Announces Insiders’ Intention to Purchase up to 10% of Public Market Securities
1
5
26
BriaCell is pleased to announce positive initial efficacy data in its 2021-2022 cohort of 12 advanced
#breastcancer
patients. For details: $BCTX $BCTXW
1
13
28
Dr. William V. Williams, BriaCell’s President & CEO, comments on the Company's positive End of Phase II meeting with the FDA for Bria-IMT™ in combination with a checkpoint inhibitor, in advanced metastatic
#breastcancer
. Find details here: $BCTX $BCTXW
1
8
24
Our company is developing novel therapies to destroy cancer. Find more information here: $BCTX $BCTXW
0
8
24
Dr. Williams’ Presentation at Benzinga Small Cap Conference – Dec 2021
5
6
23
BriaCell to Present at the AACR 2022; Provides Corporate Buyback and Insider Buying Update
2
4
25
BriaCell’s CSO Dr. Miguel A. Lopez-Lago comments on the research collaboration and license agreement between BriaCell and
@ImmunoPrecise
's subsidiary
@BioStrandBV
to discover & develop anti-cancer antibodies. $BCTX $BCTXW $IPA
0
6
26
BriaCell's lead drug candidate, Bria-IMT™ (awarded Fast Track designation by the FDA), is an
#immunotherapy
that activates the body's own cancer-fighting cells to attack and destroy
#breastcancer
tumors. Learn more: $BCTX $BCTXW
2
6
25
BriaCell Therapeutics Corp. had a stellar 2021. Check out the highlights from their previous year in the latest video by Small Cap Voice! $BCTX
#breastcancer
#clinicaltrials
#cancertherapies
#advancedbreastcancer
2
3
21
Awarded Fast Track status by the U.S. Food and Drug Administration (FDA), BriaCell’s lead candidate, Bria-IMT™, is being evaluated in a Phase II clinical trial in advanced
#breastcancer
. Learn about Bria-IMT™: $BCTX $BCTXW
0
6
25
BriaCell reported unprecedented preliminary survival & clinical benefit data in a new subset of advanced
#breastcancer
patients treated with BriaCell’s Bria-IMT™ regimen: patients that have developed resistance to Antibody-Drug Conjugates. $BCTX $BCTXW
1
2
24
.
@SaranyaChumsri
,
@MayoClinic
Professor and Principal Clinical Investigator (left) and
@CarmenCalfa
, Principal Clinical Investigator,
@SylvesterCancer
(right) with our poster
@SABCSSanAntonio
. $BCTX $BCTXW
#MBC
#SABCS22
0
4
24
BriaCell reports updated survival data from its previously disclosed group of 12 patients in the ongoing Ph. II clinical trial evaluating Bria-IMT™ in combination w/ Incyte's retifanlimab for the treatment of advanced metastatic
#breastcancer
. $BCTX $BCTXW
3
6
22
BriaCell reported positive clinical and quality of life data in advanced metastatic breast cancer at the 2022
@SABCSSanAntonio
. For more information on
#SABCS2022
posters: $BCTX $BCTXW
1
4
24
BriaCell advances preparatory work for new Bria-OTS™ breast cancer clinical trial
2
5
21
BriaCell is pleased to announce that it has received an Issue Notification from the
@uspto
for the composition of matter and method of use of its personalized off-the-shelf cell-based
#immunotherapy
for cancer. Read more: $BCTX $BCTXW
2
10
23
Learn how Bria-IMT™ and Bria-OTS™ destroy cancer cells:
$BCTX $BCTXW
0
6
23
BriaCell Reports 12.0 Months Overall Survival Benefit in Advanced Breast Cancer; 100% Resolution of ‘Eye-Bulging’ Tumor
5
6
21
BriaCell Presents Development Details of Bria-OTS™ Platform Technology at the American Association for Cancer Research (AACR) Annual Meeting 2022
1
6
21
BriaCell is dosing advanced
#breastcancer
patients in its Phase I/II clinical trial of Bria-IMT™ (awarded Fast Track designation by FDA) , with
@Incyte
’s drug, retifanlimab, under corporate collaboration with Incyte. Learn more: $BCTX $BCTXW
0
6
21
Even though two women with breast cancer may have the same size tumour, the individual characteristics of the tumour—the receptors, the genetics, even the way the tumour cells gather fuel to grow, can differ.
Learn more about
#immunotherapy
here.
0
7
19
Dr. Williams comments on BriaCell's positive survival data from its ongoing Phase II clinical trial evaluating Bria-IMT™ in combination with Incyte’s retifanlimab for the treatment of advanced metastatic
#breastcancer
. Find details here: $BCTX $BCTXW
4
3
18
BriaCell reports benchmark-beating patient survival and clinical benefit in advanced metastatic breast cancer. For details: $BCTX $BCTXW
2
7
21
BriaCell Partners with Waisman Biomanufacturing to Manufacture and Supply Prostate Cancer Immunotherapy
#breastcancer
#breastcancertreatments
#cancertreatments
#cancer
#research
#cash
#Biotechnology
0
4
21
BriaCell is thrilled to announce a new remarkable responder in our Phase 2 study of the Bria-IMT™ combination regimen. For additional details, visit: $BCTX $BCTXW
1
7
21
BriaCell Therapeutics Presents Clinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2021
1
10
16
BriaCell expects to initiate a Bria-OTS™ clinical study under an Investigational New Drug Application (IND) in the first half of 2023, in accordance with new FDA guidance. Read more here: $BCTX $BCTXW
2
4
20
BriaCell Therapeutics Corp. Announces Closing of US$27.2 Million Private Placement
2
5
16
BriaCell Announces Securities Buyback to Purchase up to 10% of Common Shares and up to 10% of Listed Warrants
3
8
18
BriaCell Summarizes Clinical Data Poster Presented at the 2021 San Antonio Breast Cancer Symposium®
9
7
18
BriaCell has reported impressive early safety and efficacy data with its lead
#immunotherapies
for the treatment of advanced breast cancer.
Read the full article from
@BioTuesdays
to learn more. $BCT
1
1
10
We are looking forward to our poster presentation, "An off-the-shelf personalized cellular approach to
#immunothrapy
for the treatment of advanced solid tumors" at the 2022 Society for Immunotherapy of Cancer Annual Meeting on November 10th. $BCTX $BCTXW
1
7
17
Dr. Williams, BriaCell's CEO, joins
@NorthEquities
to discuss the Company's positive
#breastcancer
efficacy data with Bria-IMT™
#immunotherapy
presented in a recent poster session at the
@sitcancer
37th Annual Meeting. $BCTX $BCTXW
1
7
17
BriaCell is developing Bria-OTS™, a novel off-the-shelf personalized immunotherapy for advanced breast cancer. Learn more:
#immunotherapy
$BCTX $BCTXW
0
7
18
BriaCell announced that it has added Mayo Clinic, Jacksonville, Florida, as a clinical site in the Phase I/II study of BriaCell’s lead candidate, Bria-IMT™, with Incyte’s PD-1 inhibitor, retifanlimab, in advanced breast cancer. $BCTX $BCTXW
0
8
19
An Interview with Dr. Williams Hosted by Richard De Sousa of RICH TV LIVE
1
4
17
Dr. Bill Williams, BriaCell’s President & CEO, joined
#EmpoweredPatientPodcast
host
@KarenJagoda
to discuss the company's personal cellular approach to
#breastcancer
#immunotherapy
. Listen to the podcast here: $BCTX $BCTXW
1
7
17
Prevail Partners, LLC, an investment fund and affiliate of InfoWorks, has agreed to purchase 463,408 BriaCell common shares at a price of $8.63 for gross proceeds of $4 million, representing a 20% premium to the trailing 30 trading day VWAP. $BCTX $BCTXW
0
3
17
BriaCell reported a powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular pain in a patient that failed 7 prior regimens, after only 3 cycles of the Bria-IMT™ combination regimen. Learn more: $BCTX $BCTXW
1
3
18
BriaCell is developing Bria-OTS™, the first “off-the-shelf” personalized
#immunotherapy
for the treatment for advanced stage
#breastcancer
. Read about Bria-OTS™: $BCTX $BCTXW
0
5
16
BriaCell's lead drug candidate, Bria-IMT™ (awarded Fast Track designation by the FDA) stimulates the body’s own cancer-fighting cells to attack and destroy
#breastcancer
tumors. Find more information here: $BCTX $BCTXW
1
4
16
BriaCell is made up of an expert management team with an impressive drug development and management track record. Meet our team here: $BCTX $BCTXW
1
3
16
BriaCell released transformational images of the recently reported remarkable responder in the Phase 2 study of BriaCell’s Bria-IMT™ combination regimen. Find details: $BCTX $BCTXW
1
3
16
BriaCell is developing Bria-OTS™, an “off-the-shelf” (i.e. premade) personalized
#immunotherapy
for the treatment for advanced
#breastcancer
. Learn more: $BCTX $BCTXW
0
3
16
BriaCell recently reported a median overall survival (OS) in advanced
#breastcancer
patients treated with Bria-IMT™+ CPI of 13.4 months (vs. 6.7-9.8 months for similar patients reported in the literature). For more information: $BCTX $BCTXW
0
3
16
Chief Medical Officer Dr. Giuseppe Del Priore comments on the favorable safety profile shown in the Phase I portion of the trial of BriaCell's Bria-IMT™ in combination with Incyte’s retifanlimab in advanced
#breastcancer
: $BCTX $BCTXW
1
4
17
BriaCell is conducting a Phase I/II combination study of Bria-IMT™ (awarded Fast Track designation by the FDA) with Incyte’s checkpoint inhibitor, retifanlimab for the treatment of advanced
#breastcancer
. Learn more about the trial here: $BCTX $BCTXW
0
5
17
Positive efficacy data from BriaCell's Phase I/IIa clinical study of Bria-IMT™ in combination with Incyte’s retifanlimab for the treatment of advanced
#breastcancer
was summarized in our poster session at the
@sitcancer
37th Annual Meeting. $BCTX $BCTXW
3
5
15
Dr. Del Priore, BriaCell’s Chief Medical Officer, comments on the addition of Mayo Clinic, Jacksonville, Florida as a clinical site in the Phase I/II study of Bria-IMT™ with Incyte's PD-1 inhibitor, retifanlimab, in advanced
#breastcancer
. $BCTX $BCTXW
0
3
16
#Immunotherapies
have become the forefront of cancer treatments by awakening the body’s immune system to fight and destroy cancer cells. Immunotherapies offer longer survival rates and less side effects compared with those of chemotherapies. $BCTX $BCTXW
0
3
15
BriaCell President & CEO, Dr. Williams, and CMO, Dr. Giuseppe Del Priore will provide a pipeline overview and highlight the next steps for the Phase 3 study, and will be available to answer questions during the KOL event on October 26th. $BCTX $BCTXW
0
3
15
BriaCell is pleased to announce the completion of the Phase I portion of the clinical trial of its lead candidate, Bria-IMT™, in combination with Incyte’s PD-1 inhibitor, retifanlimab, in advanced
#breastcancer
. $BCTX $BCTXW
1
5
15
BriaCell Announces $4 Million Strategic Investment and Clinical Alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc. $BCTX $BCTXW
#breastcancer
1
6
15
Under the terms of the agreement,
@carisls
will help BriaCell with efficient patient identification, accelerating enrollment for its current Ph I/II clinical trial in advanced metastatic breast cancer of certain genetically defined subgroups. $BCTX $BCTXW
1
4
12
October is
#BreastCancerAwarenessMonth
. Awarded Fast Track status by FDA, BriaCell's lead candidate is being tested in a Phase I/II clinical trial in advanced
#breastcancer
(
#metastaticbreastcancer
). For more info, please visit:
#breastcancerawareness
1
5
15
Learn about the mechanism of action of BriaCell's Bria-IMT™ and Bria-OTS™: $BCTX $BCTXW
0
2
15
The tumor reductions observed in heavily pretreated patients highlight the potential clinical benefit of Bria-IMT™ in managing CNS metastases. $BCTX $BCTXW
1
3
14
BriaCell announced plans to spin-out certain pre-clinical pipeline assets of the Company. Click here for details: $BCTX $BCTXW
1
3
15
BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment
0
4
14
BriaCell intends to use the
@theNCI
grant funds for the development of Bria-OTS™, the Company's novel personalized off-the-shelf
#immunotherapies
for advanced metastatic
#breastcancer
, prostate cancer, lung cancer, and melanoma. Learn more: $BCTX $BCTXW
1
2
15
Wishing you a wonderful Thanksgiving holiday filled with good health and happiness from the BriaCell team!
0
2
15
BriaCell Therapeutics Attacks Cancer with Novel Off-the-Shelf Immunotherapies
1
3
14
BriaCell President and CEO, Dr. William V. Williams, highlights the 71% central nervous system response rate reported in advanced
#breastcancer
patients being treated with BriaCell’s Bria-IMT™ regimen. $BCTX $BCTXW
2
1
15
Bria-OTS™, is an “off-the-shelf” (i.e. premade) personalized
#immunotherapy
for the treatment of advanced
#breastcancer
. Read more: $BCTX $BCTXW
0
5
14
In his letter to shareholders, Dr. Williams highlights the significance around BriaCell's recent FDA milestone and provides insights into upcoming catalysts. Read the letter to shareholders here: $BCTX $BCTXW
0
3
13
Chief Medical Officer, Dr. Giuseppe Del Priore, comments on the CNS tumor reductions demonstrated in five of seven patients being treated with BriaCell’s Bria-IMT™ regimen. $BCTX $BCTXW
0
1
14
BriaCell Secures License for a Promising Novel Anti-Cancer Agent
#breastcancer
#breastcancertreatments
#cancertreatments
#cancerawareness
#investing
#stockinvestment
#cancer
#research
#biotechnology
#prostatecancer
#cash
0
7
15
Saranya Chumsri, M.D., Mayo Clinic Professor and Principal Clinical Investigator, comments on the positive clinical & quality of life data with Bria-IMT™
#immunotherapy
in advanced metastatic
#breastcancer
presented at
#SABCS22
. $BCTX $BCTXW
0
4
15
BriaCell's lead asset, Bria-IMT™ is a targeted
#immunotherapy
that both indirectly and directly stimulates the body’s own cancer-fighting cells to attack and destroy
#breastcancer
tumors. Learn more: $BCTX $BCTXW
1
3
15
BriaCell’s President and CEO, Dr. William V. Williams, comments on the newly announced $4 Million strategic investment and clinical alliance with Prevail Partners, LLC and Prevail InfoWorks, Inc. $BCTX $BCTXW
0
2
15
BriaCell Therapeutics Expands Breast Cancer Platform Technology into Prostate, Melanoma, and Lung Cancers
2
8
11
BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board
1
2
13
BriaCell is conducting a Phase I/II clinical trial of its lead candidate, Bria-IMT™ (awarded Fast Track designation by the FDA), with
@Incyte
's drug, retifanlimab, an anti-PD-1 antibody, for the treatment of advanced
#breastcancer
. $BCTX $BCTXW
1
5
14
BriaCell recently announced positive clinical and quality of life data in advanced metastatic
#breastcancer
at the 2022
@SABCSSanAntonio
. Find the details here: $BCTX $BCTXW
#SABCS22
0
5
13
Two additional clinical sites are now active in BriaCell's randomized Phase II study of Bria-IMT™, with Incyte’s PD-1 inhibitor, retifanlimab, to broaden patient access:
@Carle_org
, Urbana, Illinois, & the
@AONcologyLLC
, Baltimore, Maryland. $BCTX $BCTXW
1
0
14
BriaCell's Dr. Williams, joins Stephanie Comello of
@oncologytube
to discuss the Company's recently announced positive clinical & quality of life data with Bria-IMT™
#immunotherapy
presented in poster sessions at the 2022
@SABCSSanAntonio
. $BCTX $BCTXW
0
4
14
BriaCell's novel
#immunotherapies
have been shown to activate the immune system through multiple mechanisms, leading to enhanced clinical efficacy and prevention of immune escape. Learn more: $BCTX $BCTXW
1
3
14
Positive clinical data presented at SABCS includes tumor shrinkage, disease control, progression free survival, & potential long term survival benefit in advanced metastatic
#breastcancer
patients treated with Bria-IMT™ combination regimen. $BCTX $BCTXW
0
3
13
BriaCell Enters Research Agreement to Identify Novel Targets for Cancer Treatment
#breastcancer
#breastcancertreatments
#cancertreatments
#cancer
#research
#cash
1
2
14
Positive clinical and quality of life data from BriaCell's lead product candidate, Bria-IMT™ was summarized in three poster sessions during the 2022
@SABCSSanAntonio
. Copies of BriaCell's
#SABCS2022
posters can be found here: $BCTX $BCTXW
0
4
14
We believe that Bria-IMT™ attacks tumor cells both indirectly and directly by activating the patient's immune system, which collectively destroys tumor cells. Learn more: $BCTX $BCTXW
0
2
14
BriaCell is revolutionizing the fight against
#breastcancer
with Bria-IMT™, a targeted
#immunotherapy
that has the potential to activate the body's natural defenses to attack and destroy tumors. $BCTX $BCTXW
2
2
14
.
@SaranyaChumsri
, M.D.,
@MayoClinic
Professor and Principal Clinical Investigator, commented on the positive clinical & quality of life data with Bria-IMT™
#immunotherapy
in advanced metastatic
#breastcancer
presented at
#SABCS22
. $BCTX $BCTXW
0
2
13